Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference
Phio Pharmaceuticals (NASDAQ: PHIO) will present at the 3rd Annual DealFlow Discovery Conference on January 28, 2026 at the Borgata Hotel in Atlantic City, NJ.
Rhea-AI Summary
Phio Pharmaceuticals (NASDAQ: PHIO) will present at the 3rd Annual DealFlow Discovery Conference on January 28, 2026 at the Borgata Hotel in Atlantic City, NJ. Robert Bitterman, CEO and Chairman, will deliver the company presentation on January 28 at 9:00 AM ET in Borgata Hotel Room #1, and management will be available for one-on-one investor meetings during the event.
The company noted completion of treatment in the Phase 1b trial for PH-762 and emphasized ongoing development of therapeutics using its proprietary INTASYL gene silencing technology targeting cancer.
Positive
- None.
Negative
- None.
Details
News Market Reaction – PHIO
On Jan 26, the day this news came out, PHIO closed 4.59% below the previous close.
Data tracked by StockTitan Argus for the Jan 26 session.
Key Figures
- Q3 2025 net loss
- $2.392 million
- Quarter ended September 30, 2025
- Cash & equivalents
- $10.705 million
- As of September 30, 2025
- Warrant proceeds
- $13.4 million
- Gross proceeds from inducement warrant exercises
- Registered warrant shares
- 11,763,800 shares
- Shares covered by S-3 resale registration
- Potential warrant cash
- $24.5 million
- Maximum cash if all registered warrants exercised
- Shares outstanding
- 10,764,428
- As of November 11, 2025
- Share price
- $1.09
- Prior to DealFlow conference news
- Overall response rate
- 70%
- PH-762 squamous cell carcinoma Phase 1b data
Historical Context
-
Reported 70% overall response in PH-762 cutaneous carcinoma Phase 1b trial.
-
Announced Sidoti Micro-Cap conference presentation and PH-762 clinical update access.
-
FDA accepted PH-762 nonclinical protocol; interim Phase 1b responses reported.
-
Completed enrollment in Phase 1b trial of PH-762 for multiple skin cancers.
-
Announced podium talk on INTASYL siRNA drug technology at industry congress.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
sirna medical
phase 1b medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ET
King of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ.
Robert Bitterman, CEO and Chairman of the Board of Phio Pharmaceuticals will deliver a company presentation on January 28th at 9 AM in Borgata Hotel Room #1 and the management team will be available for one-on-one investor meetings throughout the event.
"All investors are invited to join this event to learn more about Phio Pharmaceuticals and our continuing pursuit towards a cancer free future using our INTASYL technology," stated Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals. "Completion of treatment in the Phase 1b trial for PH-762 marks a significant step forward in advancing a promising treatment option for skin cancer."
Event Details are as follows:
3rd Annual DealFlow Discovery Conference
The Borgata Hotel, Casino & Spa
Atlantic City, NJ
January 28-29, 2026
Investors interested in scheduling a meeting with Phio Pharmaceuticals management team can register (Investors - DealFlow Discovery Conference) to attend the conference at no cost.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL® gene silencing technology focused on immuno-oncology therapeutics. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The ongoing Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.
For additional information, visit the Company's website, www.phiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Examples of forward-looking statements contained in this press release include, among others, the possibility that our INTASYL® siRNA gene silencing technology will make the body's immune cells more effective in killing cancer cells, the potential for PH-762 to present a viable non-surgical alternative for skin cancer, expectations regarding timing of enrollment, the expectations that we have sufficient capital to complete the treatment phase of our ongoing Phase 1b clinical trial, and statements regarding our clinical strategy, development plans and timelines and other future events.
These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, results from our preclinical and clinical activities, our ability to execute on business strategies, the timing or likelihood of regulatory filings and approvals, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/281484
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.